PubMed Trending Research Digest — October 09, 2026

Automated digest · 96 articles · 15 research areas · October 09, 2026

Overview

This week’s digest is dominated by a unifying idea: biology is increasingly being explained through mechanistic circuits—molecular, cellular, and systems-level—rather than single-gene or single-pathway stories. Across cancer, neurodegeneration, and infectious disease, studies connect upstream signals (metabolic substrates like lactate, redox state, lipid mediators, or immune cues) to downstream functional outcomes (drug resistance, immune escape, tissue repair, or transmission). Structural and multi-omic approaches (e.g., cryo-EM spliceosome/transport machines, long-read/Hi-C enhancer mapping, single-cell/spatial atlases) repeatedly show that context—chromatin architecture, cell state, spatial neighborhood, and timing—determines what a pathway “does.”

A second theme is the push toward earlier intervention and precision stratification. Trials and observational studies in Parkinson’s, hereditary angioedema, ovarian cancer, oligometastatic breast cancer, and multiple sclerosis all emphasize timing (early disease, neoadjuvant windows, on-demand attack treatment) and patient selection (biomarkers, real-world effectiveness, risk prediction). In parallel, developmental and lineage-tracing work (DNA recorders, organoid models, placental immune continua) provides the conceptual scaffolding for why early states matter—because fate decisions and immune programs are established dynamically.

Finally, the microbiome and immune system continue to emerge as causal levers. Several studies link microbial composition or microbial products (flagellin, gut taxa, metabolites like pentadecanoic acid, calprotectin regulation) to inflammation, vaccine reactions, atherosclerosis, and neonatal infection risk. Together with immune-engineering advances (CAR-T metabolic tuning, tolerance organoids/engineered lymph node niches, splicing biomarkers for ICI response), the overall picture is of medicine moving toward interventions that are both mechanistically targeted and measurable in real-world biology.

---

Cancer genomics, translocations, and regulatory circuitry

Dynamics of human cardiogenesis and its disruption in trisomy 21.

The study used single-cell and spatial multiomics to map human cardiogenesis niches and to examine how trisomy 21 disrupts developing heart organization, including high-resolution profiling of the developing sinoatrial node. It defined 21 tissue niches and resolved three pacemaker cell subtypes arranged along a linear axis, with first-trimester pacemaker subpopulations showing neuroattractant programs and altered interactions relevant to pacemaker organization. These findings provide a mechanistic, cell-niche-level framework for how trisomy 21 perturbs cardiac development and may inform targeted strategies to mitigate congenital heart disease risk.

Cranley J, Kanemaru K, Bayraktar S et al. · Nature · (2026) · View on PubMed ↗ · Free PDF ↗

RNA catalysis emerges from dynamic structural ensembles.

The study investigated how RNA structure and Mg2+ dynamics enable catalysis by using a heterogeneity-focused cryo-electron microscopy analysis of RNase P RNA ensembles. It determined that RNase P RNA exists as 76 coexisting active and inactive conformers differing by a transient tertiary interaction critical for activity, and that accessory protein binding induces thermodynamic allostery that enhances catalysis by altering tertiary-interaction dynamics. This near-atomic ensemble view clarifies how RNA catalysis emerges from dynamic structural heterogeneity and Mg2+ coupling.

Degenhardt MFS, Degenhardt HF, Bhoge BA et al. · Nature · (2026) · View on PubMed ↗ · Free PDF ↗

tRNA dosage regulates lineage dependency and resistance in prostate cancer.

The study examined prostate cancer lineage plasticity and therapy resistance by performing unbiased small RNA sequencing to identify tRNA regulators and by testing how tRNA1Arg(UCU) affects androgen receptor (AR)-targeted therapy sensitivity. It found that tRNA1Arg(UCU) reprograms lineage dependence and can be tuned to restore sensitivity to therapies targeting the androgen receptor, with TARDBP and ZSCAN29 directly engaging the genomic locus of tRNA1Arg(UCU) to regulate its expression. These results link specific tRNA dosage control to transcriptional regulation of lineage switching, offering a potential lever to overcome AR-therapy resistance in prostate cancer.

Kim YS, Arora S, Young D et al. · Nature · (2026) · View on PubMed ↗ · Free PDF ↗

Astrocytes regulate axonal mitochondrial transport deficits in C9ORF72 amyotrophic lateral sclerosis motor neurons.

The study tested whether astrocytes influence axonal mitochondrial transport deficits in C9ORF72 ALS by using cocultures of C9ORF72-mutant and isogenic gene-corrected human iPSC-derived astrocytes with motor neurons. It showed that C9ORF72 astrocytes disrupt mitochondrial axonal transport and mitochondrial function in motor neurons, while correcting the astrocytes or boosting astrocytic mitochondrial bioenergetics rescues the transport deficits. This demonstrates a non-cell-autonomous astrocyte-driven mechanism for mitochondrial transport failure in ALS models, supporting astrocyte-targeted therapeutic strategies.

Stavrou M, Heffernan ÁB, Carter RN et al. · Nature neuroscience · (2026) · View on PubMed ↗ · Free PDF ↗

Metabolic benefits of ketohexokinase inhibition in individuals with MASLD: a randomized placebo-controlled crossover trial.

The study evaluated metabolic effects of ketohexokinase inhibition using PF-06835919 in a randomized, placebo-controlled crossover trial in 15 participants with metabolic dysfunction-associated steatotic liver disease (MASLD). It reported that 6-week PF-06835919 treatment improved hepatic insulin sensitivity (primary endpoint) assessed by insulin-stimulated suppression of endogenous glucose production and assessed additional effects on fat distribution, peripheral/adipose insulin sensitivity, and fat oxidation. These clinical trial data support ketohexokinase as a druggable target in MASLD with potential cardiometabolic benefit.

Koene EJC, Schrauwen-Hinderling VB, Basset-Sagarminaga J et al. · Nature metabolism · (2026) · 1 citations · View on PubMed ↗

Towards broader-spectrum direct-acting antivirals against RNA viruses.

This Nature Reviews Microbiology article reviewed the rationale and strategies for developing broader-spectrum direct-acting antivirals against RNA viruses. It emphasizes building diversified portfolios of orally available, potent antivirals that can act across multiple genera or entire viral families to address unmet needs and improve epidemic/pandemic preparedness. The review’s significance is in guiding translational drug discovery toward mechanisms and design principles that can generalize across diverse RNA viruses.

Thibaut HJ, Jochmans D, Van Dijck C et al. · Nature reviews. Microbiology · (2026) · View on PubMed ↗ · Free PDF ↗

Diverse infections transcriptionally reprogram the intestinal epithelium and epithelial-immune cell interactions.

The study characterized how diverse infections reshape the intestinal epithelium and epithelial–immune communication by generating GutPath, an atlas of >500,000 single cells with RNA and protein profiles across 91 ileal cell states. It found that GutPath captures established immune responses while revealing pathogen-specific transcriptional programs in enterocytes, enabling mapping of infection-specific epithelial-immune interactions. This provides a high-resolution resource for understanding how different pathogens reprogram gut biology and may guide infection- and disease-tailored interventions.

Hart A, Merolle M, Howard C et al. · Nature immunology · (2026) · View on PubMed ↗ · Free PDF ↗

Next-generation immune cell engagers for B cell depletion in autoimmune diseases.

This Nature Reviews Drug Discovery article reviewed next-generation immune cell engagers (ICEs) designed for B cell depletion in autoimmune diseases. It highlights modular ICE architectures that recruit T cells, NK cells, γδ T cells, or myeloid cells to eliminate B cells, plasmablasts, and long-lived plasma cells, and discusses autoimmune-specific challenges such as B cell heterogeneity and implications for resistance and toxicity. The significance is in consolidating design considerations that could improve depth and durability of B cell depletion beyond what has been achieved in hematologic malignancies.

Fu Y, Robert B, Bitoun S et al. · Nature reviews. Drug discovery · (2026) · View on PubMed ↗

A cytoskeleton-associated Plasmodium protein critical for organelle segregation.

The study investigated organelle segregation in the malaria parasite Plasmodium falciparum by identifying and characterizing a cytoskeleton-associated protein, PfOGRE (PF3D7_1435600), required for segregation during schizogony/segmentation. Using immunofluorescence and ultrastructure expansion microscopy, it showed that PfOGRE localizes to structures needed for one-per-cell segregation of the mitochondrion and apicoplast. This identifies a specific cytoskeletal factor critical for parasite organelle partitioning, suggesting a potential target for antimalarial intervention.

Navarro FM, Wagner E, Kraemer S et al. · Nature communications · (2026) · View on PubMed ↗ · Free PDF ↗

Deep learning CT signature for predicting early liver metastases in pancreatic ductal adenocarcinoma.

The study developed and validated a Mamba-based deep learning CT signature to predict early liver metastases (ELM) in pancreatic ductal adenocarcinoma (PDAC). In a multi-institutional cohort of 1063 PDAC patients, the model achieved AUCs of 0.806–0.890 for ELM prediction and identified high-risk patients with worse progression-free and overall survival (PFS HR=1.93; OS HR=1.89). Clinically, this imaging-based risk stratification could help select patients who may benefit from neoadjuvant therapy by targeting those most likely to develop early liver metastases.

Zhao B, Gong Z, Xiao W et al. · Nature communications · (2026) · View on PubMed ↗ · Free PDF ↗

Tislelizumab plus lenvatinib in advanced fumarate hydratase-deficient renal cell carcinoma: a single-arm, phase 2 trial with metabolic biomarker analysis.

This phase 2 single-arm trial studied first-line tislelizumab (anti–PD-1) plus lenvatinib in patients with advanced fumarate hydratase-deficient renal cell carcinoma (FH-RCC), using metabolic biomarker analyses to characterize response. The combination achieved an objective response rate of 95% with 100% disease control rate, median progression-free survival of 20.7 months, median duration of response of 19.2 months, and a 2-year overall survival rate of 89.7%. These results support tislelizumab plus lenvatinib as a promising regimen for a rare, aggressive FH-RCC subtype and motivate further biomarker-driven optimization.

Kong W, Xu Y, Liu G et al. · Nature communications · (2026) · View on PubMed ↗ · Free PDF ↗

CBX4 stabilizes NEUROD1 through SUMO-ubiquitin crosstalk to delay β-cell senescence.

The study examined how Chromobox 4 (CBX4) regulates β-cell aging and function in the context of type 2 diabetes mellitus, focusing on molecular interactions with the transcription factor NEUROD1. CBX4 expression declined in aged and diabetic pancreatic islets, and Cbx4 deletion in β-cells accelerated senescence, impaired glucose tolerance, and disrupted mitochondrial function by directly interacting with NEUROD1 and promoting SUMOylation via a SUMO-interacting motif. This identifies a CBX4–NEUROD1 SUMO-ubiquitin crosstalk mechanism that could be targeted to delay β-cell senescence in T2DM.

Su L, Liu Y, Hu Q et al. · Nature communications · (2026) · View on PubMed ↗ · Free PDF ↗

Pregnancy establishment in cattle without embryonic interferon tau.

The study tested the canonical ruminant paradigm that embryonic interferon tau (IFNT) is indispensable for maternal recognition of pregnancy by using CRISPR-Cas9 loss-of-function models in cattle. IFNT-null embryos (generated by somatic cell nuclear transfer from bovine fibroblasts lacking functional copies of the multigene IFNT locus) developed to blastocysts normally in vitro and supported full-term gestation without IFNT. This overturns the assumption that IFNT is required for pregnancy establishment in cattle and reshapes understanding of maternal recognition signaling in ruminants.

Ali A, Zakhartchenko V, Güngör T et al. · Nature communications · (2026) · View on PubMed ↗ · Free PDF ↗

A core transcriptional regulatory circuitry controls super-enhancer-driven activation of LGR5 in colorectal cancer.

The study investigated the transcriptional regulatory circuitry controlling super-enhancer-driven activation of LGR5 in colorectal cancer, focusing on master transcription factors and co-activators. It found that MYC actively regulates cancer-type specific super-enhancer activity and forms a super-enhancer-dependent core circuitry with ETS2 and FOXP1, working with BRD4 to drive transcription of super-enhancer-controlled genes, while perturbing these factors sensitized colon cancer cells to BET inhibition. This mechanistically links a defined MYC–ETS2–FOXP1–BRD4 network to LGR5 stemness programs and suggests a therapeutic vulnerability to BET inhibitors.

Ye M, Wang S, Chen Y et al. · Nature communications · (2026) · View on PubMed ↗ · Free PDF ↗

Bioengineering strategies for improving the immunogenicity of mRNA vaccines.

This review article studied bioengineering strategies aimed at improving the immunogenicity of mRNA vaccines across different disease indications. It synthesized how antigen design, RNA architecture, and delivery systems modulate innate sensing and intracellular trafficking, and emphasized that indication-specific requirements (e.g., for cardiovascular, neurodegenerative, autoimmune, and metabolic disorders) limit one-size-fits-all approaches. The work is significant for guiding rational mRNA vaccine engineering to optimize both innate and adaptive immune responses for broader therapeutic use.

Wang H, Zhuo R, Wu J et al. · Signal transduction and targeted therapy · (2026) · View on PubMed ↗ · Free PDF ↗

Glucose-induced histone lactylation confers metformin resistance in colorectal cancer stem cells.

The study examined how glucose availability affects metformin sensitivity in CD133+ colorectal cancer stem cells (CSCs) and the epigenetic/metabolic mechanisms involved. Under high glucose, metformin resistance increased as cells shifted from glucose dependence to lipid use, with LDHA-dependent lactate production driving histone H3 lysine 18 lactylation (H3K18la) that activated c-JUN and induced CD36 to promote fatty acid uptake, lipid droplet formation, and β-oxidation for ATP/NADPH. This identifies a glucose–lactate–H3K18la–CD36 axis that could be targeted to overcome metformin resistance in colorectal CSCs.

Li XR, Deng L, Zhang TG et al. · Nature communications · (2026) · View on PubMed ↗ · Free PDF ↗

Histone H4K5 lactylation-driven feedback loop modulates glycerol-linked immunosuppressive activity of tumor-associated T regulatory cells.

The study investigated how histone H4K5 lactylation regulates immunosuppressive function of tumor-associated regulatory T (Treg) cells in colorectal cancer liver metastases. Using single-cell analysis of autologous patient samples and spatial transcriptomics, it identified a distinct CD177+GK+ Treg subset in metastatic lesions that localizes at the tumor-adjacent interface and interacts with immunosuppressive macrophages, and it reported a lactylation-driven feedback loop that modulates their glycerol-linked immunosuppressive activity. This suggests that targeting H4K5 lactylation pathways could reprogram metastatic Tregs to improve anti-tumor immunity.

Wang W, Kong B, Huang C et al. · Signal transduction and targeted therapy · (2026) · View on PubMed ↗ · Free PDF ↗

Phospholipid phosphatase 2 drives liver repair and regeneration after acute liver injury.

The study examined metabolic changes that initiate hepatocyte regeneration after acute liver injury, focusing on phospholipid metabolism and phospholipid phosphatase 2 (PLPP2). Multi-time-point multi-omics analyses showed dynamic phosphatidylethanolamine remodeling with synchronous changes in enzymes regulating PE metabolism, and PLPP2 alterations were corroborated in human liver biopsy samples from drug-induced liver injury and in a murine acute liver injury model. This positions PLPP2 as a key regulator of liver repair and regeneration and a potential therapeutic target after acute hepatic insults.

Li F, Wang Y, Chen P et al. · Signal transduction and targeted therapy · (2026) · View on PubMed ↗ · Free PDF ↗

Top Ten Tips Palliative Care Clinicians Should Know About Caring for People Receiving Critical Care for Cardiovascular Disease.

This article studied clinical guidance for palliative care clinicians caring for patients receiving critical care for cardiovascular disease, particularly those admitted to cardiac intensive care units (CICUs). It highlights the high symptom burden, risk of death during CICU hospitalization, and persistent functional and psychosocial distress among survivors, translating these realities into practical palliative care “top tips.” The significance is improved interdisciplinary care planning for critically ill cardiovascular patients by integrating palliative approaches alongside life-sustaining critical care.

Song A, Feder SL, Elmadhoun O et al. · Journal of palliative medicine · (2026) · View on PubMed ↗

Precision before incision: neoadjuvant tumor-agnostic therapies.

This review examined tumor-agnostic neoadjuvant strategies across immunotherapy, targeted agents, and antibody-drug conjugates in patients with solid tumors undergoing surgery. It reports a rationale for moving biomarker-guided therapy earlier—before resistance emerges and to optimize immune engagement—highlighting that single-agent PD-1 blockade has shown high pathologic response rates in the neoadjuvant setting. The clinical significance is that neoadjuvant, biomarker-guided “first-consideration” use may improve outcomes and enable organ preservation compared with the traditional metastatic-first approach.

Beal J, Coleman N, Liu J et al. · Trends in cancer · (2026) · View on PubMed ↗

Safety and tolerability of nonstatin LDL-cholesterol-lowering therapies: A systematic review and pairwise meta-analysis of randomized controlled trials.

This systematic review and pairwise meta-analysis evaluated the safety and tolerability of nonstatin LDL-cholesterol-lowering drugs—ezetimibe, PCSK9 monoclonal antibodies, bempedoic acid, and inclisiran—in randomized, double-blind, placebo-controlled trials. The key finding is that adverse-event reporting across these therapies is heterogeneous, and the authors synthesize harmonized tolerability outcomes to clarify comparative safety profiles. Scientifically, it provides an evidence base to guide selection of nonstatin LDL-lowering treatments for secondary prevention, familial hypercholesterolemia, and statin-intolerant patients.

Matteucci A, Bonanni M, Di Fusco SA et al. · Journal of clinical lipidology · (2026) · View on PubMed ↗

Starving but surviving: a new RNA switch rewires parasite metabolism.

This mechanistic study investigated how the RNA-binding protein TgPRO (“T. gondii parasite response to oxidation”) rewires translation to help intracellular Toxoplasma gondii survive metabolic stress during high-density infection. The key finding is that TgPRO regulates translation of mRNAs required for Fe-S cluster assembly and mitochondrial metabolism, enabling oxygen-dependent adaptation and supporting optimal in vivo parasite replication. The significance is that TgPRO-mediated translational control represents a potential targetable vulnerability in T. gondii infection.

Jocks J, Seeber F, Blume M · Trends in parasitology · (2026) · View on PubMed ↗ · Free PDF ↗

A Multicenter 13-Week Evaluation of the twiist Automated Insulin Delivery in Insulin-Treated Type 2 Diabetes: The twiist-T2D Pivotal Trial.

This multicenter, single-arm 13-week pivotal trial studied the twiist automated insulin delivery (AID) system in 307 adults with insulin-treated type 2 diabetes (ages 19–85) using baseline continuous glucose monitoring. The key finding was a mean HbA1c reduction of 0.7% (from 8.1% to 7.4%) after 13 weeks, meeting both noninferiority and superiority criteria with improved glycemic outcomes. Clinically, it supports twiist AID as an effective and tolerable technology for glycemic control in insulin-treated type 2 diabetes.

Levy CJ, Kanapka L, Graham TE et al. · Diabetes care · (2026) · View on PubMed ↗ · Free PDF ↗

Plasmodium protein kinase 2 is required for ookinete-to-oocyst transition and parasite transmission.

This study investigated the role of Plasmodium protein kinase 2 (PK2) in sexual-stage development and transmission of Plasmodium berghei using live-cell/super-resolution imaging, ultrastructural analysis, functional phenotyping, and quantitative phosphoproteomics. The key finding is that conditional PK2 depletion impairs ookinete motility, disrupts apical microneme positioning, abolishes oocyst formation, and thereby blocks transmission. The significance is that PK2 is a transmission-critical kinase and a potential target for antimalarial interventions aimed at blocking spread.

Pashley SL, Hair M, Ukegbu CV et al. · Life science alliance · (2026) · View on PubMed ↗ · Free PDF ↗

IL7R mRNA therapy enhances antitumor T cell immunity and suppresses tumor growth in preclinical tumor models.

This preclinical study tested whether IL7R (interleukin-7 receptor) mRNA delivered in lipid nanoparticles (LNPs) can enhance antitumor T-cell immunity and suppress tumor growth in syngeneic mouse models of B16 melanoma and Lewis lung carcinoma. The key finding is that IL7R mRNA therapy increases IL7R expression and remodels immune responses in a way that improves antitumor activity compared with empty LNP controls. Scientifically, it supports IL7R mRNA-LNP as a strategy to boost T-cell survival/homeostasis for cancer immunotherapy.

Rehman AU, Khan MN, Akhtar A et al. · Journal for immunotherapy of cancer · (2026) · View on PubMed ↗ · Free PDF ↗

TCASIA: an integrative atlas linking alternative splicing landscapes for cancer immunotherapy.

This study developed TCASIA, an integrative atlas linking alternative splicing landscapes to cancer immunotherapy outcomes, using harmonized data from >4000 samples across 29 cohorts. The key finding is that TCASIA uses a consensus framework (rMATS, MAJIQ, SUPPA2, SplAdder with a “2-out-of-4” approach) to generate high-confidence splicing features that associate with immune checkpoint blockade clinical phenotypes. The significance is that it provides a scalable resource to identify splicing-based predictive biomarkers for ICB response.

Zhang Y, Guo Y, Wang H et al. · Journal for immunotherapy of cancer · (2026) · View on PubMed ↗ · Free PDF ↗

PARP1-selective inhibitor DSB1559 demonstrates superior efficacy and antitumor immunity in triple-negative breast cancer.

This preclinical study evaluated the PARP1-selective inhibitor DSB1559 in models of triple-negative breast cancer, including BRCA1-associated disease contexts. The key finding is that selective PARP1 inhibition by DSB1559 yields superior antitumor efficacy and enhances antitumor immunity compared with broader PARP inhibition approaches, with a mechanistic rationale that PARP2 inhibition may contribute to hematologic toxicity. Clinically, it suggests a pathway to improve the therapeutic index of PARP inhibition by targeting PARP1 specifically.

Nelson A, Zheng KF, Wanderley CWS et al. · Journal for immunotherapy of cancer · (2026) · View on PubMed ↗ · Free PDF ↗

Quadrivalent human papillomavirus vaccination before pregnancy and pregnancy outcomes: nationwide, population based case-control study.

This nationwide, population-based matched case-control study in Sweden assessed whether quadrivalent human papillomavirus (HPV) vaccination before pregnancy affects the risk of adverse pregnancy outcomes. The key finding (as reported in the study’s design and outcomes focus) is the quantification of associations between preterm birth and related subtypes and vaccination status among 624,713 singleton births, comparing 92,620 vaccinated women to unvaccinated controls. The significance is informing maternal-fetal safety evidence for HPV vaccination timing relative to conception.

Zhang Z, Ploner A, Sengpiel V et al. · BMJ (Clinical research ed.) · (2026) · View on PubMed ↗ · Free PDF ↗

The dipeptidyl peptidase 1 inhibition landscape in bronchiectasis and its future direction.

This narrative review examined the “dipeptidyl peptidase 1 (DPP1) inhibition landscape” in bronchiectasis, focusing on how neutrophil serine proteases drive a vicious cycle of inflammation, infection, and impaired mucociliary clearance. The key finding is that DPP1 activates neutrophil maturation and contributes to NSP release at inflammatory sites, and that inhibiting DPP1 is proposed as a therapeutic strategy to reduce exacerbations and disease progression. Scientifically and clinically, it frames future directions for targeting DPP1/NSP pathways in bronchiectasis management.

Chalmers JD, Jain R, O’Donnell AE et al. · European respiratory review : an official journal of the European Respiratory Society · (2026) · View on PubMed ↗ · Free PDF ↗

Histone lactylation scarring transmits metabolic and epigenetic memory across the gut-liver axis.

The study examined how prior ulcerative colitis (UC) inflammation leaves a gut-liver metabolic and epigenetic “memory” that predisposes to metabolic dysfunction–associated steatotic liver disease (MASLD), focusing on persistent LCN2+ colonic macrophages and their histone lactylation. After colitis resolution, LCN2+ macrophages retained heightened glycolysis and durable histone H3K9 L-lactylation (H3K9la), trafficked to the liver, and amplified steatosis when mice were subsequently fed a high-fat diet (HFD). This provides a mechanistic epigenetic-cellular-organ cascade linking intestinal inflammation to delayed liver injury via H3K9la in macrophages, suggesting histone lactylation as a potential therapeutic target to interrupt gut-liver disease memory.

Dong H, Li J, Yang D et al. · Cell metabolism · (2026) · View on PubMed ↗

UBT251, a novel triple GLP-1, GIP, and glucagon receptor agonist, in adults with overweight or obesity: A multicenter, randomized phase 2 trial.

This multicenter, randomized, double-blind, placebo-controlled phase 2 trial studied the once-weekly triple agonist UBT251 (GLP-1/GIP/glucagon receptor agonist) in 205 adults with overweight or obesity without type 2 diabetes. At week 24, UBT251 produced substantially greater body-weight reductions than placebo (placebo-adjusted differences roughly −17.7% to −11.5% vs −2.0% with placebo, depending on dose), indicating dose-dependent anti-obesity efficacy. These results support UBT251 as a promising next-generation incretin-based therapy for weight loss in people with obesity, warranting further phase 3 evaluation for durability and safety.

Zhou Z, Cheng Z, Jin P et al. · Cell metabolism · (2026) · View on PubMed ↗

Diagnostic accuracy of the straight leg raise test for lumbosacral radicular pain: a systematic review with meta-analysis.

This systematic review and meta-analysis evaluated the diagnostic accuracy of the straight leg raise (and crossed straight leg raise) tests for lumbosacral radicular pain in patients with low back-related leg pain. The authors synthesized evidence from diagnostic accuracy and prediction-model studies using reference standards such as imaging, electrodiagnosis, surgery, or clinical diagnosis, with study quality assessed via QUADAS-2 or PROBAST. Clinically, the findings aim to clarify how reliably these bedside maneuvers identify radicular pain and thus guide diagnostic decision-making and downstream imaging or electrodiagnostic testing.

Nee RJ, Boyd BS, Sierra-Silvestre E et al. · Musculoskeletal science & practice · (2026) · View on PubMed ↗ · Free PDF ↗

Levistilide A alleviates pulmonary fibrosis by blocking the cation channel PIEZO1-centered signaling pathway in fibroblasts.

This preclinical study investigated whether levistilide A (LevA) can treat pulmonary fibrosis in bleomycin (BLM)-induced PF mice and in L929 fibroblast cells by targeting the PIEZO1-centered cation channel signaling pathway. LevA alleviated PF phenotypes by blocking PIEZO1-centered signaling in fibroblasts, reducing calcium signaling–mediated processes such as fibroblast growth and angiogenesis. The work supports PIEZO1-centered fibroblast signaling as a druggable mechanism and positions LevA as a potential targeted antifibrotic candidate.

Han Q, Chen R, Yang Y et al. · Phytomedicine : international journal of phytotherapy and phytopharmacology · (2026) · View on PubMed ↗

Saikosaponin A ameliorates acute lung injury by targeting eIF3f to regulate p62 ubiquitination and mitochondrial autophagy flux.

This study tested whether saikosaponin A (SSA) ameliorates poly(I:C)-induced viral-mimetic acute lung injury (ALI) in mice and BEAS-2B cells by targeting eIF3f to regulate p62 ubiquitination and mitochondrial autophagy flux. SSA improved ALI outcomes and mechanistically acted through eIF3f, altering p62 ubiquitination and restoring mitochondrial autophagy flux, thereby mitigating mitochondrial dysfunction and inflammatory/oxidative injury. These findings identify eIF3f–p62–mitophagy signaling as a mechanistic axis for SSA’s protective effects, informing potential targeted therapies for viral ALI.

Bi C, Zhao Y, Wei J et al. · Phytomedicine : international journal of phytotherapy and phytopharmacology · (2026) · View on PubMed ↗

Kidney Outcomes With GLP-1 Receptor Agonists and Tirzepatide Versus Finerenone in Type 2 Diabetes and Chronic Kidney Disease: A Real-World Cohort Study.

This retrospective real-world cohort study compared kidney outcomes in adults with type 2 diabetes (T2D) and chronic kidney disease (CKD) stages 3–4 who initiated GLP-1 receptor agonists or tirzepatide versus those who initiated finerenone. Using a TriNetX global network (July 2021–November 2025) with 1:1 propensity-score matching and follow-up up to 2.5 years, the primary composite endpoint (end-stage kidney disease, stage 5 CKD, or dialysis initiation) and eGFR slope analyses were used to assess comparative effectiveness. The results are clinically relevant for selecting kidney-protective therapies in T2D-CKD patients by benchmarking incretin-based drugs against finerenone in routine practice.

Sehtman-Shachar DR, Fishkin A, Leibowitz G et al. · Diabetes, obesity & metabolism · (2026) · View on PubMed ↗ · Free PDF ↗

Advances in Systemic Treatment of Breast Cancer.

This study evaluated comparative effectiveness of maintenance therapies to prevent relapses after a first myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) event in pediatric-onset patients. Using prospectively collected data from 13 US pediatric neuroimmunology centers (Nov 2011–Aug 2023) and including patients with MOG-IgG positivity by cell-based assay and aquaporin-4 IgG negativity, the analysis compared relapse prevention across maintenance regimens defined as ≥90 consecutive days of treatment. The findings aim to identify which maintenance strategy best reduces relapse risk in children with MOGAD, directly informing long-term management decisions.

Hurvitz SA · The New England journal of medicine · (2026) · View on PubMed ↗

Optogenetic Therapy for Restoring Aspects of Visual Function.

This open-label clinical study assessed the safety and early functional effects of ganglion cell–directed optogenetic therapy in 10 participants with blindness due to advanced retinitis pigmentosa. Each participant received a single intravitreal injection of an adeno-associated viral (AAV) vector encoding the red-shifted channelrhodopsin ChrimsonR in the worse-seeing eye, with safety as the primary endpoint and light sensitivity measures as secondary outcomes. The results are significant because they support the feasibility of late-stage optogenetic restoration of visual function and help define the risk-benefit profile for AAV-ChrimsonR gene-based vision therapy.

Sahel JA, Futterknecht S, Audo I et al. · The New England journal of medicine · (2026) · 1 citations · View on PubMed ↗

Clinical Features and Outcomes of Therapy-Related Myeloid Neoplasms After CAR T-Cell Therapy.

This multicenter retrospective cohort study characterized clinical features and outcomes of therapy-related myeloid neoplasms (t-MN) occurring after chimeric antigen receptor (CAR) T-cell therapy and compared them with t-MN after autologous hematopoietic cell transplantation (auto-HCT) or standard chemotherapy/radiation. In 399 adults with t-MN after CAR T (n=56), auto-HCT (n=98), or standard therapy (n=245), median latency was shorter after CAR T (15.2 months) than after auto-HCT or standard therapy, and nearest-neighbor latency-matched comparisons were used to assess overall survival (OS). The study clarifies whether CAR T–associated t-MN confers an independent survival disadvantage, which is important for risk counseling and post–CAR T surveillance strategies.

Jain MD, Ali A, Roman Diaz J et al. · Blood advances · (2026) · View on PubMed ↗ · Free PDF ↗

Translocation-induced enhancer rewiring reveals cryptic oncogenic circuits in multiple myeloma.

The study developed and applied TransFinder, a multiomic pipeline integrating SMRT long-read sequencing, Hi-C, H3K27ac ChIP-seq/CUT&Tag, and RNA-seq to resolve enhancer translocations and identify cryptic oncogenic circuits in multiple myeloma. TransFinder revealed that the canonical t(16;22)(q23;q11) translocation, known for activating MAF, also hijacks enhancers to activate RAB36, and it uncovered additional cryptic translocations t(5;8)(q35;q24) activating MYC and t(1;22)(q25;q13) activating CBX. This improves mechanistic diagnosis beyond routine IGH enhancer translocation testing and highlights specific enhancer–promoter neo-loops that drive multiple myeloma.

Zheng E, Li Q, Dou X et al. · Science advances · (2026) · View on PubMed ↗ · Free PDF ↗

---

Cancer microenvironment, immunity, and immune escape

Paired Single-Cell Profiling Reveals Glutathione-Dependent Immune Evasion in Breast Cancer Liver Metastasis.

Using single-cell transcriptomic sequencing of matched primary breast tumors and breast cancer liver metastases (BCLMs) from 13 treatment-naïve patients, this study characterized immune microenvironment differences and mechanisms of immune escape. Despite an immune-infiltrated metastatic microenvironment with cytotoxic T-cell expansion and inflammatory macrophage polarization and depletion of regulatory T cells, metastatic tumors evaded immune-mediated destruction. The work highlights glutathione-dependent immune evasion as a metastasis-relevant vulnerability and suggests potential therapeutic strategies to counter redox-mediated immune escape in BCLM.

Lyu C, Wang M, Wang H et al. · Cancer research · (2026) · View on PubMed ↗

A preinvasive regulatory T cell axis for lung cancer interception.

This human translational study investigated a preinvasive regulatory T cell (Treg) axis in lung cancer interception using multi-omic, cross-tissue immune profiling of patients with preinvasive lung lesions monitored by autofluorescence bronchoscopy and CT imaging. The key finding was that effector regulatory CD4+ T cells (eTreg cells) are remodeled during early tumorigenesis and form a regulatory network associated with preinvasive lesion biology. This provides a mechanistic basis for intercepting NSCLC earlier by targeting T-cell regulation before invasive disease develops.

Gamble S, Whiteman ZE, Peinador-Marín C et al. · Nature · (2026) · View on PubMed ↗ · Free PDF ↗

Epigenetic and Epitranscriptomic Regulation of Immune Checkpoint Response in Hepatocellular Carcinoma: Mechanisms, Therapeutic Targeting, and Translational Challenges.

This review synthesized evidence on how epigenetic and epitranscriptomic mechanisms regulate immune checkpoint inhibitor (ICI) responses in hepatocellular carcinoma (HCC), focusing on DNA methylation, histone modifications/chromatin remodeling, and RNA modifications. It highlights that these alterations can change tumor immune visibility by regulating antigen presentation, interferon signaling, chemokine production, T-cell recruitment/function, and immunosuppressive programs in myeloid and stromal compartments. The translational significance is that epigenetic/epitranscriptomic pathways represent actionable biomarkers and therapeutic targets to overcome immune resistance in HCC.

Zhi Y, Guo Y, Wei H et al. · Clinical and molecular hepatology · (2026) · View on PubMed ↗ · Free PDF ↗

---

Cancer therapeutics trials and comparative effectiveness

Universal Germline Genetic Testing after a Diagnosis of Cancer.

This large germline sequencing study analyzed 39,184 unselected patients with solid malignancies across 32 tumor types to test universal germline genetic testing independent of clinical suspicion, interrogating >90 cancer predisposition genes. Pathogenic variant prevalence decreased with later age at diagnosis (18.4% early-onset, 15.6% average-onset, 12.3% late-onset), supporting that age thresholds can misclassify genetic risk. The clinical significance is evidence favoring broad germline testing strategies to identify actionable hereditary cancer risk across tumor types.

Stadler ZK, Maio A, Khurram A et al. · Cancer discovery · (2026) · View on PubMed ↗

Outcomes of front-line tagraxofusp in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) in a real-world scenario.

This retrospective real-world multicenter study evaluated front-line tagraxofusp (TAG), a CD123-directed protein-drug conjugate, in 32 patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) treated from 2019–2024 across 13 tertiary centers. The key finding was an overall response rate of 82.1% with complete responses reported (with additional outcomes and the role of up-front consolidation described in the full text) compared against a historical pre-TAG cohort (n=40). Clinically, it supports the effectiveness of frontline TAG in routine practice and helps contextualize consolidation strategies in older, advanced BPDCN patients.

Schroeder JC, Faustmann P, Janjetovic S et al. · Journal of hematology & oncology · (2026) · View on PubMed ↗ · Free PDF ↗

T-cell-redirecting therapies in early relapsed multiple myeloma: a systematic review and network meta-analysis.

This systematic review and Bayesian network meta-analysis compared T-cell-redirecting therapies (including CAR T cells and bispecific antibodies) versus daratumumab–pomalidomide–dexamethasone in randomized phase 3 trials for early relapsed multiple myeloma after at least one prior line. Indirect pseudo-individual patient time-to-event reconstruction from published survival curves suggested a hierarchy favoring cell therapy, but the relative benefit in early relapse was specifically evaluated because prior comparisons in heavily pretreated patients had favored cell therapy. These findings help guide evidence-based selection of CAR T versus bispecific antibody strategies for early relapsed multiple myeloma where direct head-to-head data are limited.

Merz M, Souto Filho JT, Voorhees PM et al. · Journal of hematology & oncology · (2026) · View on PubMed ↗ · Free PDF ↗

Immunotherapy and targeted therapy plus hepatic arterial infusion chemotherapy for HCC with portal vein tumor thrombosis (CHANCE2504): a nationwide target trial emulation study.

Using a nationwide target trial emulation framework with clone-censor-weighting (CCW) across 36 Chinese centers, this retrospective study evaluated first-line safety and efficacy of immune checkpoint inhibitors (ICIs) plus molecular-targeted agents (MTAs) with or without hepatic arterial infusion chemotherapy (HAIC) for hepatocellular carcinoma with portal vein tumor thrombosis (PVTT). The key finding was the comparative effectiveness and safety of these ICI+MTA±HAIC strategies in a PVTT population with dismal prognosis, aiming to resolve uncertainty in optimal sequencing and combination. This is significant because it informs real-world treatment selection for advanced HCC with PVTT while approximating evidence from a target trial.

Lin LW, Chen Q, Zhou JW et al. · Clinical and molecular hepatology · (2026) · View on PubMed ↗ · Free PDF ↗

Neoadjuvant niraparib monotherapy for unresectable, homologous recombination deficiency-positive, high-grade serous ovarian cancer (NANT): a multicentre, single-arm, phase 2 trial.

In a multicentre, single-arm phase 2 trial (NANT), investigators tested neoadjuvant niraparib monotherapy as a chemotherapy-free approach in unresectable, homologous recombination deficiency (HRD)-positive high-grade serous or endometrioid ovarian cancer initially unsuitable for primary debulking surgery. The study evaluated feasibility and clinical outcomes of niraparib in this HRD-positive population, targeting improved cytoreduction without conventional neoadjuvant chemotherapy. This is clinically significant because it explores a PARP inhibitor–based neoadjuvant strategy that could expand options for patients who cannot undergo optimal upfront surgery.

Liu D, Peng Z, Zhang W et al. · The Lancet. Oncology · (2026) · View on PubMed ↗

NRG-BR002: A Randomized Phase II/III Trial of Metastasis-Directed Ablation With First-Line Systemic Therapy for Oligometastatic Breast Cancer.

This randomized phase II/III trial (NRG-BR002) studied whether metastasis-directed ablation added to first-line systemic therapy improves progression-free survival in patients with oligometastatic breast cancer (≤4 metastases) whose primary disease was controlled and whose visible metastases were amenable to SBRT or surgical resection. The trial compared metastasis-directed ablation plus systemic therapy versus first-line systemic therapy alone. If positive, this would establish a strategy to improve outcomes by integrating local ablative treatment during initial systemic management of oligometastatic disease.

Chmura SJ, Winter KA, Woodward WA et al. · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · (2026) · View on PubMed ↗

---

Cancer metabolism and epigenetic regulation (incl. lactylation)

Lactate-H3K18la-RPL11 Axis Drives Gemcitabine Resistance in Pancreatic Cancer by Integrating Protein Synthesis and DNA Damage Repair.

This mechanistic cancer study investigated how lactate-driven histone H3K18 lactylation (H3K18la) regulates gemcitabine resistance in pancreatic ductal adenocarcinoma by controlling ribosomal protein L11 (RPL11)-dependent protein synthesis and DNA damage repair. It found that gemcitabine-induced lactate accumulation increases H3K18la, which activates RPL11 transcription, and that RPL11 promotes survival via cytoplasmic stabilization of EEF1A1 to enhance translation and nuclear coactivation involving PARP14. These findings identify the lactate–H3K18la–RPL11 axis as a potential therapeutic target to overcome gemcitabine resistance in PDAC.

Zhao L, Cao J, Liu W et al. · Advanced science (Weinheim, Baden-Wurttemberg, Germany) · (2026) · View on PubMed ↗ · Free PDF ↗

---

Neurodegeneration (Parkinson’s, ALS) mechanisms and interventions

Nicotinamide Riboside for Patients With Early-Stage Parkinson Disease: The NOPARK Randomized Clinical Trial.

This phase 3 randomized, double-blind, placebo-controlled trial (NOPARK) studied oral nicotinamide riboside, an NAD+ precursor, in patients with early-stage Parkinson disease diagnosed within 2 years (35+ years) across 11 Norwegian centers. The study tested whether prolonged nicotinamide riboside improves clinical outcomes versus placebo. If effective, this would support NAD+ augmentation as a potential disease-modifying strategy in early Parkinson disease.

Brakedal B, Skeie GO, Derad C et al. · JAMA · (2026) · View on PubMed ↗

The Gut-Brain Axis in Parkinson’s Disease: From Clinical Observation toward Mechanism-Based Precision Medicine.

This perspective article reviewed the gut-brain axis in Parkinson’s disease, focusing on how gastrointestinal dysfunction may contribute to disease initiation and progression and how objective phenotyping could enable mechanism-based precision medicine. It emphasized that GI manifestations are heterogeneous (e.g., dysphagia, gastroparesis, slow transit, defecatory dysfunction) and should be mapped to distinct biological trajectories potentially involving Lewy pathology. The scientific significance is a framework for translating clinical GI observations into mechanistic subtyping that could guide individualized PD therapies.

Scheperjans F, Borghammer P, Pfeiffer RF et al. · Movement disorders : official journal of the Movement Disorder Society · (2026) · View on PubMed ↗ · Free PDF ↗

Migraine.

This article is a clinical overview of migraine, describing the disorder as a chronic neurovascular condition with recurrent disabling attacks and emphasizing the role of genetic and epigenetic factors across neurosensory and neurovascular networks. It summarizes how mechanistic pathway research has driven development of targeted, mechanism-based therapies that are improving patient outcomes. The significance is that it frames migraine as a multi-system, biology-driven disease to support continued translation of molecular mechanisms into clinical treatment.

Tassorelli C, Wang SJ, Pozo-Rosich P et al. · Lancet (London, England) · (2026) · View on PubMed ↗

Physical Activity and Motor and Cognitive Progression in Parkinson Disease: A Longitudinal Cohort Study.

This longitudinal cohort study examined how physical activity relates to the rate of motor and cognitive progression in people with mild-to-moderate Parkinson disease enrolled in the Cincinnati Cohort Biomarker Program (2019–2025). Higher physical activity measures (including total physical activity time and volume, and components such as vigor) were associated with slower progression of motor and cognitive outcomes over time. These findings support physical activity as a potentially modifiable factor in PD progression and identify specific activity components that could be targeted in clinical interventions.

Ryu DW, Duque KR, Marsili L et al. · Neurology · (2026) · View on PubMed ↗

Human microglia clear intraneuronal α-synuclein aggregates by GPNMB-mediated trogocytosis.

Using iPSC-derived coculture models of human dopaminergic neurons and human microglia, this study investigated how microglia clear de novo or fibril-triggered intraneuronal α-synuclein aggregates in the context of α-synuclein gene triplication and Parkinson disease–relevant pathology. Microglia cleared Ser129-phosphorylated α-synuclein aggregates via a contact-dependent trogocytosis mechanism, modulated by sensing through P2RY12 and inhibition through CD22. These results identify a specific microglial clearance pathway and molecular regulators that could be leveraged to enhance early protective responses in Parkinson disease.

Chueh HJ, Katsikoudi A, Aragón-González A et al. · Science translational medicine · (2026) · View on PubMed ↗

---

Neuro-oncology (glioma, craniopharyngioma, neuroblastoma)

Spatial omics resolves adrenergic and mesenchymal cell states in neuroblastoma.

This study used single-cell/single-nucleus RNA sequencing (sc/snRNA-seq), bulk RNA-seq, spatial transcriptomics, and spatial proteomics to analyze 54 neuroblastoma tumors and resolve adrenergic (ADRN) versus mesenchymal (MES) tumor cell states and heterogeneity across patients. Tumor cells occupied distinct spatial neighborhoods and the authors identified MES states in patient tumors more reliably than prior approaches that relied on cell-line features alone. The work improves mechanistic understanding of neuroblastoma lineage plasticity and provides a spatially grounded framework for targeting MES-associated biology in patients.

Patel AG, Ashenberg O, Collins NB et al. · Cancer cell · (2026) · View on PubMed ↗

Integrated multi-omics analyses decipher molecular subtype-associated tumor microenvironment patterns in glioma.

This work integrated bulk and single-cell transcriptomics, spatial transcriptomics, and proteomics from glioma tissues and patient blood to characterize tumor microenvironment (TME) patterns associated with isocitrate dehydrogenase (IDH) molecular subtypes. IDH-wildtype glioma showed a more complex TME enriched in pericytes and immune cells, whereas IDH-mutant glioma exhibited distinct subtype-associated molecular patterns with prognostic relevance. The multi-omics, subtype-resolved TME characterization can improve risk stratification and guide subtype-specific therapeutic strategies in glioma.

Huang GH, Zhu ML, Yan Q et al. · Cancer letters · (2026) · View on PubMed ↗

---

Cardiovascular disease (atherosclerosis, thrombosis, amyloidosis) and vascular biology

Immunoregulatory gene GIMAP6 suppresses lethal atherosclerotic vasculopathy and ischemic heart failure.

Researchers investigated the role of the immunoregulatory gene Gimap6 in mice by assessing how Gimap6 loss affects vascular inflammation, atherosclerosis, and ischemic heart failure in the absence of hyperlipidemia. Gimap6 deficiency caused inflammatory vasculopathy, accelerated atherosclerosis, endothelial barrier failure, and a mitochondrial ROS–PPARγ–CD36 lipid-influx cascade that lowered the threshold for foam-cell formation, culminating in progressive cardiac ischemia, myocardial infarction, heart failure, and early death. These results identify GIMAP6 as a protective regulator of vascular homeostasis and suggest that modulating the ROS–PPARγ–CD36 axis could be a therapeutic strategy for preventing lethal atherosclerotic vasculopathy.

Xiang C, Arusha K, Springer D et al. · Cell · (2026) · View on PubMed ↗

Epigenetic aging and transposon dysregulation reflect size-related lifespan compression in dogs.

Using 1640 methylomes from 894 dogs, this study developed an epigenetic clock to quantify epigenetic aging and relate it to lifespan compression, including analysis of transposon dysregulation and methylation at orthologs of human age-associated genes. Epigenetic aging predicted mortality and was fastest early in life, with larger and male dogs showing accelerated molecular aging and distinct sex- and size-related methylation architectures, alongside transposon dysregulation. These results support conserved epigenetic mechanisms of aging and suggest that intrinsic aging rates can compress lifespan, informing comparative biology and potential interventions targeting epigenetic and transposon pathways.

Mariner BL, McCoy BM, Greenier A et al. · Science (New York, N.Y.) · (2026) · View on PubMed ↗

Neurologic Stability During Tafamidis Treatment in Transthyretin Amyloidosis with a Mixed Phenotype: A Multicenter Real-World Study.

This multicenter, retrospective real-world cohort study assessed neurologic stability in adults with mixed-phenotype transthyretin amyloidosis treated with tafamidis free acid 61 mg for at least 12 months. The key finding was that neurologic measures (and other clinical outcomes) could be tracked pre- versus post-treatment in routine practice, providing evidence on tafamidis’ real-world effectiveness in this mixed-phenotype population. Clinically, the study supports more informed expectations for neurologic outcomes with tafamidis in patients with mixed ATTR amyloidosis beyond trial populations.

Fine NM, Streicher NS, Conceição I et al. · Cardiology and therapy · (2026) · View on PubMed ↗ · Free PDF ↗

Aberrant erythrocyte rigidity in JAK2V617F myeloproliferative neoplasms underlies concurrent thrombosis and hemorrhage.

This study examined how the JAK2 Val617→Phe (JAK2V617F) mutation affects hemostasis and thrombosis by testing red blood cell (RBC) mechanics in humans and lineage-specific JAK2V617F knockin mice (Jak2F/+Vav-Cre). JAK2V617F produced structurally aberrant clots with prolonged clot formation times and impaired whole-blood clot contraction even when mutant erythrocytes were resuspended in normal plasma, indicating an RBC-intrinsic contribution to clot pathology. The findings link a driver mutation in MPNs to altered RBC mechanical behavior, suggesting new mechanistic targets for preventing both thrombosis and hemorrhage.

Suzuki A, Zhao L, Thorsheim C et al. · Science translational medicine · (2026) · View on PubMed ↗

Epigenetic insights into extreme longevity in the world’s oldest terrestrial animal, Jonathan.

The study investigated molecular correlates of extreme longevity by sequencing the genome and methylome of the 194-year-old Aldabra giant tortoise “Jonathan” and comparing them with other Aldabra individuals across ages. Jonathan carried unique gene variants across most aging pathways and showed substantial DNA methylation and methylation-entropy changes, with low-entropy methylation regions enriched at promoters of mitochondrial electron transport chain and RNA metabolism genes. These findings suggest that altered epigenetic organization—particularly at mitochondrial and RNA-regulatory promoters—may contribute to exceptional longevity in a long-lived terrestrial animal.

Vaisvil B, Schmitt DP, Jones A et al. · Science advances · (2026) · View on PubMed ↗ · Free PDF ↗

---

Infectious disease, vaccines, and antiviral/antimalarial targets

Thermal proteome profiling identifies new drug targets in Plasmodium falciparum parasites.

The study used proteome-wide cellular thermal shift assay (MS-CETSA) combined with computational molecular docking to screen 25 antimalarial drugs in Plasmodium falciparum and identify their binding targets, including validation of known targets and discovery of new ones. It confirmed ACS10 as the target of MMV665915 and identified additional previously unrecognized drug targets, while updating the MS-CETSA pipeline with a membrane solubilization step to validate targets such as atovaquone and cipargamin. This provides a scalable thermal-proteomics strategy to map drug–protein interactions in P. falciparum and supports rational development of next-generation antimalarials as resistance to current drugs increases.

Pazicky S, Dziekan JM, Tjia S et al. · Molecular & cellular proteomics : MCP · (2026) · 2 citations · View on PubMed ↗ · Free PDF ↗

Hospital-based prevalence of culture-confirmed melioidosis among high-risk patients in India, 2023-25: a multicentre prospective study.

This multicentre prospective hospital-based prevalence study enrolled adults (≥18 years) hospitalized with predefined community-acquired infectious syndromes plus diabetes or chronic kidney disease across 15 tertiary care centers in India from 2023–2025 to estimate culture-confirmed melioidosis prevalence. The key finding was the measured hospital-based prevalence of culture-confirmed melioidosis among these high-risk inpatients. This is important for public health because it addresses under-recognition in India and supports improved surveillance and diagnostic prioritization in high-risk groups.

Gupta N, Ashiq M, Kumar TP et al. · The Lancet. Global health · (2026) · View on PubMed ↗ · Free PDF ↗

Fusion-loop-engineered Zika mRNA vaccine elicits convergent B cell immunodominance to uncouple protection from ADE in macaques.

The study engineered a Zika virus fusion-loop (FL) mRNA vaccine (ZIKV-M/E) and tested it in macaques to evaluate protection against ZIKV challenge while minimizing dengue virus (DENV) antibody-dependent enhancement (ADE). It found that FL-engineered ZIKV-M/E mRNA vaccination elicited highly ZIKV-specific B cells (>97%) dominated by a convergent population using a germline ortholog of human IGHV5-10-1, with negligible DENV ADE. This is significant because it demonstrates primate-level immunogen design that decouples protection from ADE risk, advancing safer flavivirus vaccine development.

Yang C, Guo S, Lu Y et al. · Cell reports. Medicine · (2026) · View on PubMed ↗ · Free PDF ↗

---

Microbiome and host–microbe interactions

The human gut microbiome primes fever after vaccination.

This longitudinal human study profiled fecal microbiota, oral temperature, and serological markers in 171 healthy adults receiving SARS-CoV-2 mRNA vaccines to determine what primes fever risk. Fever risk correlated with low-grade intestinal inflammation, increased flagellated Lachnospiraceae abundance, and higher flagellin expression before vaccination, and microbiomes from fever-high donors triggered stronger inflammation in human intestinal organoids and flagellin-dependent vaccine reactions in gnotobiotic mice. The findings implicate microbiome flagellin as a modifiable driver of vaccine-associated fever and provide a mechanistic basis for predicting and potentially mitigating adverse reactions.

Huus KE, Abo H, Tan YH et al. · Science (New York, N.Y.) · (2026) · View on PubMed ↗

Prehistoric global migration of vanishing gut microbes with humans.

This study used deep metagenomic sequencing to reconstruct the evolutionary history of gut microbes across human populations, focusing on long-term residents that have vanished in industrialized settings. The key finding was evidence for prehistoric global migration patterns associated with the loss or disappearance of specific gut microbial taxa in modern industrialized populations. Scientifically, it links human demographic history to gut microbiome biodiversity loss, informing hypotheses about how microbial extinction may affect present-day health.

Carter MM, Liu Z, Olm MR et al. · Nature · (2026) · 1 citations · View on PubMed ↗ · Free PDF ↗

A gut microbial odd-chain fatty acid alleviates atherosclerosis in mice.

This mouse study tested whether the gut bacterium Bacteroides uniformis and its metabolite pentadecanoic acid (PA; C15:0) causally affect atherosclerosis. The key finding was that B. uniformis administration alleviated atherosclerosis by upregulating hepatic low-density lipoprotein receptor expression, and bioactivity-guided screening identified PA as a principal bioactive metabolite that reduced plaque burden by about 50% with supplementation. These results support a causal gut–liver–lipid mechanism and nominate PA as a candidate metabolite for therapeutic exploration in atherosclerosis.

Yin C, Chen Y, Lin G et al. · Nature · (2026) · 1 citations · View on PubMed ↗

Exploratory clinical and immunological changes following Tixagevimab/Cilgavimab administration in immunodeficient patients with SARS-CoV-2-associated ME/CFS and persistent circulating spike protein.

In a prospective, non-randomized observational study of 10 immunodeficient long-COVID-associated ME/CFS patients with persistent circulating SARS-CoV-2 spike protein (n=9 for paired analysis), investigators measured changes after administration of the spike-targeting monoclonal antibodies tixagevimab/cilgavimab. The key finding was that the study assessed whether spike protein concentrations and autonomic receptor autoantibodies changed over 30 days and whether clinical outcomes shifted, in the context of persistent circulating spike. This is clinically relevant because it tests whether anti-spike monoclonal therapy can modulate persistent antigen and immune/autoimmune correlates proposed in long-COVID pathophysiology.

Seidel M, Anft M, Wiemers L et al. · Immunology letters · (2026) · View on PubMed ↗

Early-life microbiota direct an epithelial S100 program required for neonatal immunity.

In neonatal mouse models, this study tested how early-life microbiota shape neonatal immunity by regulating intestinal S100A8/S100A9 (calprotectin) expression. Commensal colonization at birth drove high calprotectin levels, and impaired calprotectin expression or lack of microbiota increased susceptibility to sepsis and death after infection, while calprotectin administration rescued microbiota-depleted pups. The work identifies a microbiota-calprotectin axis as a key determinant of neonatal immune readiness and a potential therapeutic target to prevent early-life infections.

Negi S, Hashimoto-Hill S, Waddell A et al. · Science translational medicine · (2026) · View on PubMed ↗

---

Developmental biology, embryogenesis, and lineage tracing

Comprehensive lineage tracing maps the landscape of cell fate decisions in mouse embryogenesis.

This work developed and applied PEtracer, a method that continuously installs heritable genetic marks during development, to perform comprehensive lineage tracing across >1.4 million cells from 16 replicate mouse embryos and paired deep transcriptional profiling. The authors reconstructed lineage trees resolving ~75% of cell divisions and quantified fate biases, restriction timing, progenitor pool sizes, and lineage relationships throughout mouse embryogenesis. The resulting quantitative lineage reference maps reproducible cell fate decision architecture and provides a scalable framework for studying how developmental trajectories are established.

Colgan WN, Koblan LW, Villagrana J et al. · Cell · (2026) · View on PubMed ↗

A DNA Typewriter records the cell lineage history of a mouse, from zygote to late organogenesis.

This study applied the DNA Typewriter sequential molecular recorder to track cell lineage history in a mouse from zygote through late organogenesis over nearly two weeks, reconstructing a time-calibrated phylogeny from 1.28 million transcriptionally profiled cells. Editing events marked the daughters of the first cleavage, and the authors quantified clonal dominance and temporal clade co-occurrence, showing that tree siblings share cell types above chance and heterotypic siblings correspond to terminal differentiation. The approach provides a high-resolution, time-calibrated lineage map that can be used to test how developmental fate decisions unfold across mammalian development.

Yu Q, Kim H, Seidel S et al. · Science (New York, N.Y.) · (2026) · View on PubMed ↗

Alveolar stem cells transdifferentiate to drive bronchiolar regeneration.

This mouse study used dual-recombinase-mediated lineage tracing to test whether alveolar cells contribute to bronchiolar repair after injury. The key finding was that alveolar type 2 (AT2) cells migrate into injured bronchioles and transdifferentiate into club cells and ciliated cells, with infiltrating immune cells secreting SPP1 to establish a chemotactic gradient that supports this process. These results identify a reciprocal alveolar-to-airway regenerative route, informing strategies to enhance bronchiolar regeneration after lung injury.

Liu K, Liu Z, Meng X et al. · Nature · (2026) · View on PubMed ↗ · Free PDF ↗

A multiomic atlas reveals distinct immune landscapes in preterm and term chronic placental inflammation.

This multiomic atlas study profiled placental and extraplacental tissues from preterm and term pregnancies using imaging mass cytometry, single-cell RNA sequencing, spatial transcriptomics, and T cell receptor (TCR) repertoire mining to define immune determinants of chronic placental inflammation (CPI). CPI was found to represent a gestational-age-dependent immune continuum rather than a single uniform inflammatory state, with distinct immune features distinguishing preterm from term CPI. These findings improve mechanistic stratification of CPI across gestation and could inform more precise risk assessment and interventions for preterm birth.

Levenson D, Romero R, Pique-Regi R et al. · Science translational medicine · (2026) · View on PubMed ↗ · Free PDF ↗

Rapid protamine evolution suppresses meiotic drive in Drosophila.

The study investigated how rapid evolution of the Drosophila protamine gene Mst77F affects meiotic drive, using in vivo gene replacement with divergent orthologs in Drosophila melanogaster. Replacing Mst77F caused DNA compaction defects in X-bearing sperm, reducing mature X-bearing sperm and producing male-biased progeny, with dosage changes of Mst77F orthologs similarly biasing outcomes and ortholog dosage rescue restoring them. These findings show that fast protamine evolution can suppress meiotic drive by altering sex-chromosome–specific sperm chromatin packaging, linking sperm chromatin evolution to reproductive conflict.

Chang CH, A de la Cruz AF, Lai HY et al. · Science advances · (2026) · View on PubMed ↗ · Free PDF ↗

Endogenous retrovirus control of calbindin is essential for human early embryogenesis.

The study examined whether human endogenous retrovirus HERVH regulatory elements control the expression of the calcium-binding gene CALB1 during early human embryogenesis, using evidence from human embryonic stem cells and evolutionary genomic context. It showed that HERVH integration on chromosome 8q21.3 during Homininae evolution coincided with acquisition of CALB1 expression, and that HERVH control of calbindin is essential for human early embryogenesis. This links specific HERVH cis-regulatory integration events to a functional developmental gene program, with implications for how endogenous retroviruses shape early development and cancer biology.

Pape J, McCarthy A, Serna-Morales E et al. · Science advances · (2026) · View on PubMed ↗ · Free PDF ↗

---

Cell biology and molecular mechanisms (splicing, translation, organelles, membranes)

Golgi-derived vesicles containing PI(3,4)P2 drive mitochondrial fusion.

Researchers investigated how Golgi-derived vesicles enriched in PI(3,4)P2 regulate mitochondrial fusion by combining cell biology experiments with perturbations of class II PI3-kinases (PI3K-C2α and PI3K-C2β) that generate PI(3,4)P2. They found that PI(3,4)P2-containing Golgi vesicles are recruited to ER- and mitofusin-marked fusion sites and that loss of PI3K-C2α/β impaired mitochondrial fusion. These results identify a lipid- and vesicle-mediated mechanism linking Golgi signaling to mitochondrial membrane remodeling, with implications for understanding organelle dynamics in cell fate regulation.

Aki S, Segawa M, Anton V et al. · Science (New York, N.Y.) · (2026) · View on PubMed ↗

C1qc Mediates Blood-Brain Barrier Disruption in a Mouse Model of Intracerebral Haemorrhage Through Microglia-Derived Migrasomes.

This preclinical mouse study of intracerebral hemorrhage (ICH) investigated how microglia-derived migrasomes disrupt the blood-brain barrier (BBB) and identified C1qc as a key mediator. It found that C1qc accumulates around hematomas and worsens BBB disruption through migrasome-mediated pathways, with single-cell RNA-seq–based clustering and Mendelian randomization used to nominate key ICH-associated genes. Scientifically, it implicates the microglia migrasome–C1qc axis as a potential target to limit secondary brain injury after ICH.

Li M, Li Z, Song D et al. · Journal of extracellular vesicles · (2026) · View on PubMed ↗ · Free PDF ↗

Mechanism of spliceosome termination.

This mechanistic study used cryo-electron microscopy to determine how the human spliceosome terminates after intron excision. The key findings were that the RNA helicases DHX15 and Aquarius unwind the RNA active site to release components and extract the intron-lariat branch point, followed by debranching by the spliceosome-tethered enzyme DBR1 to generate a debranched intron spliceosome. These structural insights clarify the molecular steps that enable spliceosome recycling and intron decay, informing understanding of splicing regulation and potential spliceosome-related disease mechanisms.

Boreikaite V, Faraway R, Vorländer MK et al. · Nature · (2026) · View on PubMed ↗ · Free PDF ↗

5-oxoETE links redox control of epithelial damage detection and resilience.

This study used live zebrafish and human cells to identify a metabolic redox signaling pathway linking oxidative stress to epithelial damage detection and resilience via the lipid mediator 5-oxoETE. The key finding was that the orphan short-chain fatty acid dehydrogenase–reductase DHRS7 generates or consumes 5-oxoETE depending on the cytoplasmic NADP+/NADPH ratio, with wounds showing conditions that drive 5-oxoETE production. Scientifically, it connects redox control to inflammatory lipid signaling, suggesting a targetable pathway for modulating tissue repair and resilience.

Ma Y, Lengyel M, Hui KL et al. · Nature · (2026) · View on PubMed ↗ · Free PDF ↗

Structural basis for regulating lipopolysaccharide transmembrane transport.

This structural biology study determined how the lipopolysaccharide (LPS) transport (Lpt) machine regulates LPS transmembrane transport across the bacterial envelope. Using three structural snapshots of the trans-envelope Lpt complex, the key finding was a structural basis for regulation of LPS movement across the Lpt bridge, addressing whether transport itself is controlled during growth. This mechanistic insight can inform antibiotic development targeting LPS transport to disrupt Gram-negative outer membrane biogenesis.

Taylor RJ, Pahil KS, Caruso A et al. · Nature · (2026) · View on PubMed ↗ · Free PDF ↗

Ribosome remodeling drives translation adaptation during viral infection and cellular stress.

This mechanistic study investigated how ribosome composition is remodeled to adapt translation during viral infection and cellular stress in human cells. It found that infection by non-segmented negative-sense viruses recruits the large subunit protein rpL40 to a non-canonical site on the small subunit near the mRNA entry site, producing specialized ribosomes that preferentially bind viral mRNAs to enhance viral protein synthesis under host pressures. The significance is that it identifies a translation-control mechanism—ribosome remodeling via rpL40—that could be targeted to limit viral replication.

Tsai HY, Liu L, Fleming RH et al. · Molecular cell · (2026) · View on PubMed ↗

Atomic structure and dynamics of the mechanosensitive channel MscL from Escherichia coli by cryo-EM and solid-state NMR.

This structural biology study determined the atomic structure and dynamics of the mechanosensitive channel MscL from Escherichia coli, comparing wild-type and the Gly22→Ser (G22S) mutant. Using cryo-EM in peptide-based lipid nanodiscs and solid-state NMR in liposomes, the authors found a closed conformation for wild-type by cryo-EM and widespread conformational changes for the low-threshold G22S mutant captured by NMR across cytoplasmic and periplasmic regions. These results provide mechanistic insight into how specific mutations alter MscL gating and advance understanding of mechanotransduction in native-like membranes.

Xiao T, Kovinko A, Shi C et al. · Science advances · (2026) · View on PubMed ↗ · Free PDF ↗

Real-time single-molecule imaging in zebrafish embryos uncovers noncanonical translation.

The study used ALFA array-based nascent chain labeling combined with lattice light-sheet microscopy, together with MS2/MCP labeling of bmp2b mRNA, to visualize translation kinetics in early zebrafish embryos. Only a subset of bmp2b mRNAs were actively translated at single-molecule resolution, indicating that translation efficiency is governed by noncanonical kinetic steps rather than uniform initiation across all transcripts. These results provide an in vivo, single-molecule framework for how developmental regulators like bmp2b are selectively produced during embryogenesis.

Bellec M, Liang J, Mattonet K et al. · Science advances · (2026) · View on PubMed ↗ · Free PDF ↗

---

Gene therapy and advanced biomedical engineering

Human lung organoid modelling of tissue-resident antiviral T cell responses.

This study developed long-term adult human distal lung organoids from intact tissue fragments in a 3D air–liquid interface culture system to model tissue-resident antiviral T cell responses. The key finding was that the organoid platform can support epithelial infection while preserving tissue-resident immune subset behavior, enabling study of local TRM-driven antiviral responses in a human in vitro context. This advances scientific capability to dissect how tissue-resident memory T cells coordinate local immunity during respiratory infections.

Rathkey JK, Choi SS, van Unen V et al. · Nature · (2026) · View on PubMed ↗

Use of split intein and myotropic AAV vectors enables effective preclinical gene therapy for dysferlinopathy.

This preclinical gene therapy study addressed limb-girdle muscular dystrophy type R2 (dysferlinopathy) caused by mutations in the DYSF gene by developing AAV vectors that use split inteins and myotropic capsids to reconstitute full-length dysferlin. The approach enabled effective delivery and functional restoration of dysferlin expression despite the ~4.7 kb AAV packaging limit for the ~6.2 kb DYSF cDNA. These results advance a practical gene-therapy design for large genes and support further development toward treatments for dysferlinopathy.

McCormack NM, Lee-Diaz S, Reyes TR et al. · Science translational medicine · (2026) · View on PubMed ↗

Targeted integration of extrachromosomal arrays in C. elegans using PhiC31 integrase.

The study tested whether PhiC31 integrase can enable targeted, efficient integration of extrachromosomal DNA arrays in the Caenorhabditis elegans germline. Using PhiC31-mediated integration of arrays of transgenes (PhIAT) at attB sites on three chromosomes (including a fluorescent landing pad), the authors achieved extremely efficient and targeted integration compared with prior x-ray or CRISPR-based approaches. This provides a less damaging and more reliable method for building stable, chromosome-integrated transgenic lines in C. elegans.

Rich MS, Pellow R, Zhang Y et al. · Science advances · (2026) · View on PubMed ↗ · Free PDF ↗

---

Immunotherapy engineering (CAR-T, immune cell engagers, tolerance platforms)

Sodium-Glucose Cotransporter SGLT2 Supports Metabolic Fitness and Ferroptosis Resistance in CAR-T Cells to Enhance Activity Against Solid Tumors.

This study tested whether overexpressing the sodium-glucose cotransporter SGLT2 in CAR-T cells improves metabolic fitness and ferroptosis resistance under solid-tumor microenvironment stressors, using glucose restriction and high NaCl conditions and multiple solid tumor xenograft models. SGLT2 overexpression enhanced glycolysis and mitochondrial fitness, improved CAR-T activation/cytotoxicity/persistence, and increased resistance to ferroptosis, leading to stronger antitumor activity in vivo. The findings support SGLT2 as a metabolic engineering target to bolster CAR-T efficacy against solid tumors characterized by glucose deprivation and elevated sodium chloride.

Gao Y, Yang X, Mao X et al. · Cancer research · (2026) · View on PubMed ↗

Immunoregulatory artificial lymph nodes restore antigen-specific tolerance in advanced multiple sclerosis.

This study developed a 3D-printed tolerogenic artificial lymph node (tol-aLN) to restore antigen-specific immune tolerance in advanced multiple sclerosis using tolerogenic dendritic cells (tolDCs). The tol-aLN created a protected immune niche that sustained tolDC function, recruited naïve CD4+ T cells via engineered CCL21 release, and improved durable tolerance induction compared with limitations of tolDC vaccines in inflamed lymph nodes. Clinically, this supports a next-generation, tissue-engineered immunotherapy platform for antigen-specific tolerance in progressive MS.

Ji J, Wang X, Liu L et al. · Science translational medicine · (2026) · View on PubMed ↗

---

Clinical diagnostics, imaging, and risk prediction (incl. surgical risk, dental/ortho)

Oral deucrictibant for on-demand treatment of hereditary angioedema attacks: a phase 3, multicentre, randomised, double-blind, placebo-controlled crossover trial.

This phase 3, multicentre, randomised, double-blind, placebo-controlled 2×2 crossover trial studied oral deucrictibant (an oral bradykinin B2 receptor antagonist) for on-demand treatment of hereditary angioedema attacks in adolescent (≥12 to <18 years) and adult (≥18 to ≤75 years) participants across 59 sites in 24 countries. Deucrictibant provided rapid, sustained relief with improved attack resolution versus placebo in this crossover design. These findings support deucrictibant as a clinically practical oral on-demand option for bradykinin-mediated hereditary angioedema attacks, potentially enabling faster self-administration than injectable therapies.

Riedl MA, Li PH, Adatia A et al. · Lancet (London, England) · (2026) · View on PubMed ↗

New periodontal phenotype classification in patients with different types of malocclusion and dental crowding.

This cross-sectional study evaluated a cluster-based periodontal phenotype classification in 180 participants (1080 maxillary anterior teeth) with different malocclusion types and dental crowding using superimposed cone-beam computed tomography and intraoral scan data. Gingival thickness (GT) and alveolar bone thickness (ABT) were quantified to characterize how periodontal soft- and hard-tissue features vary across skeletal patterns and crowding. Clinically, this could improve orthodontic risk assessment and periodontal stability prediction by integrating imaging-derived periodontal phenotypes.

Al-Sosowa AA, Abdulghani EA, Meng W et al. · Journal of periodontology · (2026) · View on PubMed ↗

Safety and Efficacy of Repeat Surgery for Recurrent Craniopharyngiomas: A RAPID Consortium Collaboration.

This multi-institutional registry analysis (RAPID consortium; 16 US academic skull-base centers) studied outcomes of repeat surgery for recurrent craniopharyngiomas in 483 patients treated between 2000 and 2024. The key finding was the characterization of surgical outcomes and safety after reoperation for recurrent disease using registry-derived demographic, clinical, radiographic, and surgical variables. Scientifically and clinically, it informs expectations and decision-making for patients requiring repeat surgery for craniopharyngioma recurrence.

Shih RM, Harary M, Bergsneider M et al. · Neurosurgery · (2026) · View on PubMed ↗

U-Shaped Age Pattern of Erectile Dysfunction with Elevated Prevalence in Men in Their 20s Independent of Marital Status: Results from a National Survey in Japan.

This nationwide, internet-based cross-sectional survey analyzed 6,228 Japanese men aged 20–79 years to assess erectile dysfunction (ED) prevalence by age and marital status, defining ED as an Erection Hardness Score ≤2. The study found a U-shaped age pattern with elevated ED prevalence in men in their 20s that persisted independent of marital status after multivariable adjustment for comorbidities (e.g., obesity, diabetes, hypertension, dyslipidemia, CKD, cardiovascular disease, smoking). This highlights a distinct early-life ED risk signal that may require targeted prevention or evaluation beyond relationship status.

Tsujimura A, Fukuhara S, Chiba K et al. · The world journal of men’s health · (2026) · View on PubMed ↗ · Free PDF ↗

Beyond Frailty in Pancreatic Surgery: Toward a Pancreas-Specific Surgical Vulnerability Framework.

This systematic review evaluated frailty assessment tools used in pancreatic surgery and proposed a pancreas-specific surgical vulnerability framework to better capture interactions among patient vulnerability, nutrition, body composition, and procedure-specific risk. The key contribution was synthesizing evidence (PRISMA 2020-guided search, 2016–April 2026) and translating it into a conceptual framework rather than testing a single intervention. Clinically, it aims to standardize how surgical risk is measured in pancreatic operations to improve prediction of postoperative outcomes.

Marchese T, Valle V, Comandatore A et al. · World journal of surgery · (2026) · View on PubMed ↗

Targeting CD28 on T lineage malignancies with chimeric antigen receptor T cells.

The study investigated whether targeting CD28 with chimeric antigen receptor (CAR) T cells could treat T cell acute lymphoblastic leukemia (T-ALL) and related T-lineage malignancies in children/adolescents and in nodal T-follicular helper cell lymphomas. CD28 was overexpressed on T-ALL blasts and uniformly upregulated in nodal T-follicular helper cell lymphomas, and CRISPR/Cas9-mediated CD28 knockout to prevent fratricide enabled highly functional anti-CD28 CAR T cells with selective cytotoxicity against CD28+ T-ALL. This provides a rationale for CD28-directed CAR T therapy as an alternative to CD7 targeting to reduce T-cell aplasia and CD7-negative immune escape.

Willier S, Färber J, Ispyrlidou T et al. · Nature communications · (2026) · View on PubMed ↗ · Free PDF ↗

Safety and cost-effectiveness of a pure hypochlorous acid cleansing solution in wounds and non-intact skin management: a narrative review.

This narrative review evaluated the safety and cost-effectiveness evidence for a pure hypochlorous acid (pHA) cleansing solution (free of hypochlorite derivatives) for wound cleansing and non-intact skin management. The review summarizes available clinical evidence supporting pHA as providing a favorable balance of safety and efficacy compared with concerns about irritation or toxicity from some other cleansing agents. Clinically, it supports consideration of pHA in wound care protocols where minimizing cytotoxicity while maintaining cleansing effectiveness is important.

Amaya R, Armstrong DG, Chaffin AE et al. · Journal of wound care · (2026) · View on PubMed ↗

---

---

Generated automatically on October 09, 2026 from PubMed’s trending articles. Summaries are AI-generated; always consult the original publication for clinical or research decisions.